Archblock Announces Rebranding of Stablecoin Portfolio
12.9.2023 18:18:00 EEST | Business Wire | Press release
Archblock, enabling open access to financial opportunities and global trade, is thrilled to announce the rebranding of its portfolio of stablecoins, previously known as TrueCoin. The Archblock Stablecoins portfolio features fiat-backed stablecoins pegged to the GBP, CAD and AUD. The company plans to introduce an HKD stablecoin after the licensing requirements are established.
In addition to its portfolio of stablecoins, Archblock Stablecoins offers the technical and operational foundation to build white-label stablecoins for others. Archblock launched the first institutional-grade fiat-backed stablecoin, TrueUSD (“TUSD”), in 2018 as a proof of concept in asset-backed token development. TUSD has since been sold to Techteryx, who continues to operate the stablecoin. As of June 30, 2023, the market capitalization of TUSD exceeded $3.0B. With experience in building scalable white-label stablecoins, Archblock is excited to continue developing and implementing stablecoin platforms customized to meet the needs of its partners. Archblock Stablecoins services include bank-grade customer onboarding with audited KYC/AML, smart contract development and maintenance, bank integration, exchange listings for liquidity, white-labeled user-facing application for minting and redeeming, and industry-leading security.
Designed to overcome the limitations of traditional banking systems, Archblock is committed to leveraging the global potential of blockchain technology. Initially created as a secure and trusted on-and-off ramp for on-chain investors, Archblock's stablecoin offering has evolved. It now serves as the foundation for next-generation financial services, taking advantage of blockchain's transparency, immutability and efficient settlement processes. Stablecoins enable 24/7 transactions and reduce the friction and costs associated with traditional banking, and promote financial inclusion, allowing users to transact easily globally.
Alex de Lorraine, Chief Executive Officer of Archblock, stated, “Our stablecoin management system is engineered with a focus on the customer experience, catering to businesses, institutional users and retail users alike. Our stablecoins are built with transparency and regulatory compliance at the forefront. We ensure transparency and equal access to information by partnering with third parties for real-time independent attestations, external audits, and proof-of-reserves. Our aim is to use web3 enabled finance systems to democratize financial solutions that have historically been available only to those with access to traditional banking institutions. Whether investing in digital assets on-chain or transacting with businesses that accept digital currencies, our stablecoins offer a more efficient and cost-effective option.”
The Archblock Stablecoins portfolio is accessible on 12 blockchains and over 90 exchanges. It is available to all users who meet the KYC/KYB requirements.
About Archblock Stablecoins
Archblock is expanding access to financial opportunities and global trade with its Archblock Stablecoins portfolio and Archblock Marketplace. Archblock Stablecoins offers the technical and operational foundation to build white-label stablecoins for others, and operates a portfolio of fiat-backed stablecoins. For more information about Archblock Stablecoins, please contact Archblock at support@archblock.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912852354/en/
Contact information
Media Contact:
Kelly Ferraro, River North Communications
1-646-275-7040
kelly@rivernorthagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom